Fever with rash in COVID‐19: viral exanthema or secondary lesions?

Goldust, Mohamad; Abdelmaksoud, Ayman; Shuang, Z.; Xiang, Chao; Navarini, Alexander A.

doi:10.1111/jdv.16639

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 34 were selected for full text review based on their title and abstract. Full text screening resulted in the final selection of 25 articles (Figure 1), [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] reporting 26 patients with urticaria and/or angioedema and COVID-19 infection and their management plan and/or response to management. Table 1 includes the summarized key findings of the studies included in this review.…”

Section: Resultsmentioning

confidence: 99%

Management of urticaria in COVID ‐19 patients: A systematic review

Abuelgasim

Dona

Sondh

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Objectives The global pandemic COVID‐19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence in of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature and present out findings. Methods Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include “COVID‐19,” “Coronavirus”, “SARS‐Cov‐2”, “Urticaria,” “Angioedema,” “Skin rash” up to August, 01 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID‐19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Results Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema and COVID‐19 infection and their management and/or response. Majority of patients (n=16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases non‐responsive to steroids. Conclusions Management of urticarial in COVID‐19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualised basis. Further research is required in understanding urticarial pathogenesis in COVID‐19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase. This article is protected by copyright. All rights reserved.

show abstract

Section: Resultsmentioning

confidence: 99%

Management of urticaria in COVID ‐19 patients: A systematic review

Abuelgasim

Dona

Sondh

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…La morfología del exantema está compuesto por máculas, pápulas eritematosas a menudo confluentes, y ocasionalmente placas eccematoides. 11,[43][44][45] La afección de las mucosas es rara.…”

Section: Exantema Maculopapularunclassified

“…Algunos patrones sugieren vasculitis linfocítica. [43][44][45][46][47] Recientemente se han estado presentando casos de exantemas tardíos, algunos han iniciado vesiculares, posteriormente desarrollan maculopápulas confluentes que se extienden rápidamente y posteriormente descaman. 46 Habitualmente no tienen fiebre ni síntomas generales, pero podrían desarrollar leucocitosis, eosinofilia, elevación de transaminasas.…”

Section: Exantema Maculopapularunclassified

Las mil caras de la piel en enfermos con enfermedad COVID-19

Garza¹,

Ochoa²,

Perera³

2021

Acta Médica Grupo Ángeles

View full text Add to dashboard Cite

Se desconoce la frecuencia real de las manifestaciones cutáneas asociadas con la infección por SARS-CoV-2. Aun con técnicas avanzadas de inmunohistoquímica con proteínas virales, el hallazgo del virus en la piel es controvertido, por ello se consideran lesiones paravirales. La fisiopatología de estos daños por COVID-19 es compleja y su morfología heterogénea. Los mecanismos citotóxicos del SARS-CoV-2 parecen causar estimulación de los mastocitos, daño endotelial, dilatación vascular, infiltración perivascular y periglandular por linfocitos y neutrófilos, daño de interfaz y en ocasiones necrosis epidérmica focal. Los mecanismos de defensa contra la infección parecen contribuir a la génesis de las lesiones reportadas, así como la toxicidad directa del virus, la activación humoral y celular inmediata y tardía, las respuestas inmunes; la tormenta de citoquinas con microtrombosis y la probable activación de otros virus (herpes 6-7). El uso de múltiples fármacos puede desempeñar un papel importante. Desde el punto de vista clínico, los pacientes presentan un amplio espectro de combinaciones de lesiones elementales. Aun cuando en informes de series europeas se reporta una alta incidencia de lesiones inflamatorias acrales. En México las erupciones maculopapulares son las manifestaciones más frecuentes. Existe una gran cantidad de diagnósticos diferenciales, infecciones virales, bacterianas, parasitarias y cuadros clínicos reaccionales, los cuales deben seguir siendo considerados.

show abstract

“…safety measures as recommended by the World Health Organization (WHO); the Center for Disease Control and Prevention (CDC); the American Academy of Dermatology (AAD); and other local, state, national, and global health organizations while treating our patients amidst the COVID-19 outbreak to reduce the risk of community transmission and protect our patients, partners, and staff. [4][5][6][7] Disinfection of practice is crucial. The WHO recommends the use of 70% ethyl alcohol to disinfect popular clinical areas between uses and sodium hypochlorite 0.5% to disinfect common surfaces.…”

mentioning

confidence: 99%